Evidence map›Paper›PMID 41024191›Full record

ArticleJournal of cheminformatics2025

MolPrice: assessing synthetic accessibility of molecules based on market value.

Friedrich Hastedt, Klaus Hellgardt, Sophia Yaliraki, Dongda Zhang, Antonio Del Rio Chanona

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Friedrich HastedtDepartment of Chemical Engineering, Imperial College London, London, UK.
Klaus HellgardtDepartment of Chemical Engineering, Imperial College London, London, UK.
Sophia YalirakiDepartment of Chemistry, Imperial College London, London, UK.
Dongda ZhangDepartment of Chemical Engineering, University of Manchester, Manchester, UK. dongda.zhang@manchester.ac.uk.
Antonio Del Rio ChanonaDepartment of Chemical Engineering, Imperial College London, London, UK. a.del-rio-chanona@imperial.ac.uk.

Funding

Engineering and Physical Sciences Research Council EP/S023232/1
6 · The paper itself

Abstract

Machine learning approaches for conceptualizing and designing in silico compounds have attracted significant attention. However, the applicability of these compounds is often challenged by synthetic viability and cost-effectiveness. Researchers introduced proxy-scores, known as synthethic accessiblity scoring, to quantify the ease of synthesis for virtual molecules. Despite their utility, existing synthetic accessibility tools have notable limitations: they overlook compound purchasability, lack physical interpretability, and often rely on imperfect computer-aided synthesis planning algorithms. We introduce MolPrice, an accurate and fast model for molecular price prediction. Utilizing self-supervised contrastive learning, MolPrice autonomously generates price labels for synthetically complex molecules, enabling the model to generalize to molecules beyond the training distribution. Our results show that MolPrice reliably assigns higher prices to synthetically complex molecules than to readily purchasable ones, effectively distinguishing different levels of synthetic accessibility. Furthermore, MolPrice achieves competitive performance on literature benchmarks for synthetic accessibility. To demonstrate its practical utility, we conduct a virtual screening case study, illustrating how MolPrice successfully identifies purchasable molecules from a large candidate library. MolPrice bridges the gap between generative molecular design and real-world feasibility by integrating cost-awareness into synthetic accessibility assessment, making it a powerful model to accelerate molecular discovery.

Indexed as

Molecular priceSelf-supervised learningSynthetic accessibilityVirtual screening

Identifiers

PMID41024191
PMCPMC12482503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.